In June the US government has agreed to purchase 20,000 doses of ABthrax™ from Human Genome Sciences. But the stockpiling of drugs against inhalational anthrax, a potential bioweapon causing an acute infectious disease resulting from inhaling spores of Bacillus anthracis, is not yet over. Still under the Project BioShield Act of 2004, the U.S. Department of Health and Human Services will acquire an additional 10,000 doses of anthrax immune globulin (AIG) for $143 million, this time from Cangene.

More information about AIG and the supply contract from Cangene's press release.